Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauermann, M. Hinteregger, V. Marković-Peković, B. Tubic, G. Petrova, K. Tachkov, J. Slabý, R. Nejezchlebova, IS. Krulichová,...

. 2021 ; 2021 (-) : 9996193. [pub] 20211011

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012100

Background: Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results: Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions: There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.

Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina 78000 Banja Luka Bosnia and Herzegovina

Centre for Primary Care and Health Services Research School of Health Sciences University of Manchester Manchester M13 9PL UK

Chair of Epidemiology and Preventive Medicine Medical College Jagiellonian University Krakow Poland

Dachverband der Österreichischen Sozialversicherungen Kundmanngasse 21 AT 1030 Vienna Austria

Department of Global Health Economics and Policy University of Kragujevac Kragujevac Serbia

Department of Global Public Health Karolinska Institutet Stockholm Sweden

Department of Health Policy and Health Economics Eotvos Lorand University Budapest Hungary

Department of Health Services Management University of Malta Valletta Malta

Department of Medical Biophysics Faculty of Medicine in Hradec Králové Charles University Simkova 870 500 03 Hradec Králové Czech Republic

Department of Pathology Forensic Medicine and Pharmacology Institute of Biomedical Sciences Faculty of Medicine Vilnius University Vilnius Lithuania

Department of Pharmacology College of Pharmacy Hawler Medical University Erbil Iraq

Department of Pharmacology Therapeutics and Toxicology Universitat Autònoma de Barcelona Barcelona Spain

Department of Pharmacy Disciplinary Domain of Medicine and Pharmacy Uppsala University Uppsala Sweden

Department of Pharmacy Faculty of Medicine University of Medicine Tirana Albania

Department of Pharmacy Practice and Policy Faculty of Health Sciences University of Namibia Windhoek Namibia

Division of Public Health Pharmacy and Management School of Pharmacy Sefako Makgatho Health Sciences University Pretoria South Africa

Drug Department Catalan Health Service Gran Via de les Corts Catalanes 08007 Barcelona Spain

Faculty of Medicine Department of Medicinal Chemistry University of Banja Luka Banja Luka Bosnia and Herzegovina

Faculty of Medicine Department of Social Pharmacy University of Banja Luka Banja Luka Bosnia and Herzegovina

Faculty of Medicine Public Health and Management Department Carol Davila University of Medicine and Pharmacy Bucharest 050463 Bucharest Romania

Faculty of Pharmacy Department of Social Pharmacy and Pharmacoeconomics Medical University of Sofia Sofia Bulgaria

Faculty of Pharmacy UBT Higher Education Institute Pristina Kosovo

Health Insurance Institute Miklosiceva 24 SI 1507 Ljubljana Slovenia

HTA Consulting Starowiślna Str 17 3 31 038 Krakow Poland

Independent Consultant Riga Latvia

Institute of Comparative Economic Studies Faculty of Economics Hosei University Tokyo Tokyo Japan

Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS Milan Italy

Medicines Committee Oslo University Hospitals Oslo Norway

National Organization for the Provision of Healthcare Services Athens Greece

NEPI Nätverk för läkemedelsepidemiologi Stockholm Sweden

NHS Lothian Edinburgh UK

NIHR Greater Manchester Patient Safety Translational Research Centre School of Health Sciences University of Manchester Manchester UK

Pharmacy Services Greater Glasgow and Clyde Glasgow UK

Public Health Scotland Gyle Square 1 South Gyle Crescent Edinburgh UK

School of Pharmaceutical Sciences Universiti Sains Malaysia Penang Malaysia

State Agency of Medicines Nooruse 1 50411 Tartu Estonia

State Institute for Drug Control Prague Czech Republic

Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow G4 0RE UK

Syreon Research Institute and Semmelweis University Center of Health Technology Assessment Budapest Hungary

Wissenschaftliches Institut der AOK Rosenthaler Straße 31 10178 Berlin Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012100
003      
CZ-PrNML
005      
20220506131119.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2021/9996193 $2 doi
035    __
$a (PubMed)34676266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Godman, Brian $u Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK $u Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa $u School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia $1 https://orcid.org/0000000165396972
245    10
$a Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications / $c B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauermann, M. Hinteregger, V. Marković-Peković, B. Tubic, G. Petrova, K. Tachkov, J. Slabý, R. Nejezchlebova, IS. Krulichová, O. Laius, G. Selke, I. Langner, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuolienė, J. Gulbinovič, PV. Bonanno, J. Rutkowski, S. Ingeberg, Ø. Melien, I. Mardare, J. Fürst, S. MacBride-Stewart, C. Holmes, C. Pontes, C. Zara, MT. Pedrola, M. Hoffmann, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark
520    9_
$a Background: Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results: Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions: There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.
650    _2
$a biosimilární léčivé přípravky $x ekonomika $x terapeutické užití $7 D059451
650    _2
$a analýza nákladů a výnosů $x trendy $7 D003362
650    _2
$a diabetes mellitus $x diagnóza $x farmakoterapie $x ekonomika $7 D003920
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x ekonomika $x terapeutické užití $7 D007004
650    _2
$a inzulin glargin $x ekonomika $x terapeutické užití $7 D000069036
650    _2
$a dlouhodobě působící inzulin $x ekonomika $x terapeutické užití $7 D049528
650    _2
$a vzdělávání pacientů jako téma $x metody $7 D010353
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wladysiuk, Magdalene $u Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland $u HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland
700    1_
$a McTaggart, Stuart $u Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK
700    1_
$a Kurdi, Amanj $u Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK $u Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa $u Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq $1 https://orcid.org/0000000150361988
700    1_
$a Allocati, Eleonora $u Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy
700    1_
$a Jakovljevic, Mihajlo $u Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia $u Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Tokyo, Japan $1 https://orcid.org/0000000291606846
700    1_
$a Kalemeera, Francis $u Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia $1 https://orcid.org/0000000243205087
700    1_
$a Hoxha, Iris $u Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania
700    1_
$a Nachtnebel, Anna $u Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria
700    1_
$a Sauermann, Robert $u Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria
700    1_
$a Hinteregger, Manfred $u Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria
700    1_
$a Marković-Peković, Vanda $u Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina $1 https://orcid.org/0000000189635720
700    1_
$a Tubic, Biljana $u Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina $u Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Petrova, Guenka $u Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria
700    1_
$a Tachkov, Konstantin $u Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria $1 https://orcid.org/0000000239617556
700    1_
$a Slabý, Juraj $u State Institute for Drug Control, Prague, Czech Republic
700    1_
$a Nejezchlebova, Radka $u State Institute for Drug Control, Prague, Czech Republic
700    1_
$a Krulichová, Iva Selke $u Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic
700    1_
$a Laius, Ott $u State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia
700    1_
$a Selke, Gisbert $u Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany $1 https://orcid.org/0000000296149875
700    1_
$a Langner, Irene $u Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany
700    1_
$a Harsanyi, András $u Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary
700    1_
$a Inotai, András $u Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary
700    1_
$a Jakupi, Arianit $u Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo
700    1_
$a Henkuzens, Svens $u Independent Consultant, Riga, Latvia
700    1_
$a Garuolienė, Kristina $u Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
700    1_
$a Gulbinovič, Jolanta $u Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
700    1_
$a Bonanno, Patricia Vella $u Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK $u Department of Health Services Management, University of Malta, Valletta, Malta
700    1_
$a Rutkowski, Jakub $u HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland
700    1_
$a Ingeberg, Skule $u Medicines Committee, Oslo University Hospitals, Oslo, Norway
700    1_
$a Melien, Øyvind $u Medicines Committee, Oslo University Hospitals, Oslo, Norway
700    1_
$a Mardare, Ileana $u Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania $1 https://orcid.org/0000000247259808
700    1_
$a Fürst, Jurij $u Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia
700    1_
$a MacBride-Stewart, Sean $u Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK $1 https://orcid.org/0000000225535939
700    1_
$a Holmes, Carol $u NHS Lothian, Edinburgh, UK
700    1_
$a Pontes, Caridad $u Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain $u Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000232746048
700    1_
$a Zara, Corinne $u Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain $1 https://orcid.org/0000000268312233
700    1_
$a Pedrola, Marta Turu $u Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain $1 https://orcid.org/0000000169573155
700    1_
$a Hoffmann, Mikael $u NEPI-Nätverk för läkemedelsepidemiologi, Stockholm, Sweden
700    1_
$a Kourafalos, Vasileios $u National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece
700    1_
$a Pisana, Alice $u Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Banzi, Rita $u Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy
700    1_
$a Campbell, Stephen $u Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK $u NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK
700    1_
$a Wettermark, Bjorn $u Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden $1 https://orcid.org/0000000305312516
773    0_
$w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2021, č. - (2021), s. 9996193
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34676266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131111 $b ABA008
999    __
$a ok $b bmc $g 1789618 $s 1163301
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 2021 $c - $d 9996193 $e 20211011 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace